Current Opinion in Pulmonary Medicine最新文献_第10页

Pulmonary rehabilitation in idiopathic pulmonary fibrosis. 特发性肺纤维化的肺康复治疗。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1097/MCP.0000000000001094

Leona M Dowman, Anne E Holland

{"title":"Pulmonary rehabilitation in idiopathic pulmonary fibrosis.","authors":"Leona M Dowman, Anne E Holland","doi":"10.1097/MCP.0000000000001094","DOIUrl":"10.1097/MCP.0000000000001094","url":null,"abstract":"Purpose of review: This review synthesizes the expanding evidence for pulmonary rehabilitation that has led to its recommended inclusion in the holistic care of people with idiopathic pulmonary fibrosis (IPF), as well as discussing strategies that may maximize and sustain benefits.Recent findings: Pulmonary rehabilitation is an effective intervention leading to significant improvements in exercise tolerance, symptoms, and quality of life for people with IPF. Improvements in symptoms and quality of life can persist longer term, whereas functional capacity does not; therefore, strategies to preserve functional capacity are an important area of research. Referral early in the disease course is encouraged to promote longer lasting effects. Evidence that high-intensity interval training may optimize benefits of exercise training is emerging. Supplemental oxygen is frequently used to manage exercise-induced desaturation, although its use as an adjunct therapy requires more evidence.Summary: Current evidence strongly supports the inclusion of pulmonary rehabilitation in the standard holistic care of IPF, with early participation encouraged. Further research is needed to establish the optimal exercise strategies, modalities and adjunct therapies that enhance outcomes of pulmonary rehabilitation and promote longer lasting effects.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"516-522"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Leveraging AI technology in sarcoidosis. 利用人工智能技术治疗肉样瘤病。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-10 DOI: 10.1097/MCP.0000000000001085

Akiff Premjee, Lawrence Li, Srilakashmi Garikapati, Kwabena Nketiah Sarpong, Adam S Morgenthau

{"title":"Leveraging AI technology in sarcoidosis.","authors":"Akiff Premjee, Lawrence Li, Srilakashmi Garikapati, Kwabena Nketiah Sarpong, Adam S Morgenthau","doi":"10.1097/MCP.0000000000001085","DOIUrl":"10.1097/MCP.0000000000001085","url":null,"abstract":"Purpose of review: Sarcoidosis is a systemic, granulomatous disease of uncertain cause. Diagnosis may be difficult, prognosis uncertain and response to treatment unpredictable. The application of artificial intelligence to sarcoidosis may provide clinical decision support for these challenges. This review will provide an overview of current and potential future applications of artificial intelligence in sarcoidosis.Recent findings: The predominant application of artificial intelligence in sarcoidosis is imaging. Imaging models may differentiate sarcoidosis from other pulmonary disorders. Models, which predict survival and identify key factors relevant to prognosis are also available. The application of cluster analysis to organize sarcoidosis patients into developmental phenotypes is underway. Machine learning algorithms to evaluate the treatment response of sarcoidosis patients do not yet exist but similar models may evaluate patients with other inflammatory disease. The potential applications of artificial intelligence to sarcoidosis is vast, but there are practical limitations that warrant consideration. These include: the accessibility of data, biases in data, cost and privacy.Summary: The application of artificial intelligence in medicine is still in its early stages but models are poised to support the diagnostic and prognostic challenges in sarcoidosis patients. The predictive power of these artificial intelligence is likely to come from combining various models, trained on content-rich datasets from phenotypically heterogeneous sarcoidosis patients.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"570-575"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases. 心肺疾病中运动性肺动脉高压的预后相关性。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1097/MCP.0000000000001096

Katarina Zeder, Philipp Douschan, Vasile Foris, Teresa Sassmann, Bradley A Maron, Horst Olschewski, Gabor Kovacs

{"title":"The prognostic relevance of exercise pulmonary hypertension in cardiac and pulmonary diseases.","authors":"Katarina Zeder, Philipp Douschan, Vasile Foris, Teresa Sassmann, Bradley A Maron, Horst Olschewski, Gabor Kovacs","doi":"10.1097/MCP.0000000000001096","DOIUrl":"10.1097/MCP.0000000000001096","url":null,"abstract":"Purpose of review: In this review, we provide an overview of the prognostic implications of exPH in patients with various common cardiac and pulmonary diseases.Recent findings: Exercise pulmonary hypertension (exPH) has been recently re-introduced in the current European Society of Cardiology/European Respiratory Society pulmonary hypertension guidelines. Accordingly, exPH is defined as a mean pulmonary arterial pressure (mPAP)/cardiac output ( CO ) slope greater than 3 mmHg/l/min. Key considerations for this re-introduction included increasing understanding on normal pulmonary hemodynamics during exercise and the broadly available evidence on the association of an abnormal mPAP/ CO slope with poor survival in the general population and in different disease entities.Summary: Exercise (patho-)physiology has opened a new field for clinical research facilitating recognition of cardiovascular and pulmonary vascular diseases in an early stage. Such early recognition with significant prognostic and possibly therapeutic relevance, but being undetectable at rest, makes exercise pulmonary hemodynamics particularly interesting for common diseases, such as valvular heart disease, left heart disease, and chronic pulmonary disease.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"451-458"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Editorial introductions. 编辑介绍。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-08-08 DOI: 10.1097/MCP.0000000000001107

引用次数: 0

What causes cough in pulmonary fibrosis, and how should we treat it? 肺纤维化患者咳嗽的原因是什么？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.1097/MCP.0000000000001087

Katherine J Myall, Peter S P Cho, Surinder S Birring

引用次数: 0

Big data in sarcoidosis. 肉样瘤病的大数据。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-05 DOI: 10.1097/MCP.0000000000001102

Natalia V Rivera

{"title":"Big data in sarcoidosis.","authors":"Natalia V Rivera","doi":"10.1097/MCP.0000000000001102","DOIUrl":"10.1097/MCP.0000000000001102","url":null,"abstract":"Purpose of review: This review provides an overview of recent advancements in sarcoidosis research, focusing on collaborative networks, phenotype characterization, and molecular studies. It highlights the importance of collaborative efforts, phenotype characterization, and the integration of multilevel molecular data for advancing sarcoidosis research and paving the way toward personalized medicine.Recent findings: Sarcoidosis exhibits heterogeneous clinical manifestations influenced by various factors. Efforts to define sarcoidosis endophenotypes show promise, while technological advancements enable extensive molecular data generation. Collaborative networks and biobanks facilitate large-scale studies, enhancing biomarker discovery and therapeutic protocols.Summary: Sarcoidosis presents a complex challenge due to its unknown cause and heterogeneous clinical manifestations. Collaborative networks, comprehensive phenotype delineation, and the utilization of cutting-edge technologies are essential for advancing our understanding of sarcoidosis biology and developing personalized medicine approaches. Leveraging large-scale epidemiological resources and biobanks and integrating multilevel molecular data offer promising avenues for unraveling the disease's heterogeneity and improving patient outcomes.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"561-569"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141533941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Applications of artificial intelligence in computed tomography imaging for phenotyping pulmonary hypertension. 人工智能在肺动脉高压表型计算机断层扫描成像中的应用。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-09 DOI: 10.1097/MCP.0000000000001103

Michael J Sharkey, Elliot W Checkley, Andrew J Swift

{"title":"Applications of artificial intelligence in computed tomography imaging for phenotyping pulmonary hypertension.","authors":"Michael J Sharkey, Elliot W Checkley, Andrew J Swift","doi":"10.1097/MCP.0000000000001103","DOIUrl":"10.1097/MCP.0000000000001103","url":null,"abstract":"Purpose of review: Pulmonary hypertension is a heterogeneous condition with significant morbidity and mortality. Computer tomography (CT) plays a central role in determining the phenotype of pulmonary hypertension, informing treatment strategies. Many artificial intelligence tools have been developed in this modality for the assessment of pulmonary hypertension. This article reviews the latest CT artificial intelligence applications in pulmonary hypertension and related diseases.Recent findings: Multistructure segmentation tools have been developed in both pulmonary hypertension and nonpulmonary hypertension cohorts using state-of-the-art UNet architecture. These segmentations correspond well with those of trained radiologists, giving clinically valuable metrics in significantly less time. Artificial intelligence lung parenchymal assessment accurately identifies and quantifies lung disease patterns by integrating multiple radiomic techniques such as texture analysis and classification. This gives valuable information on disease burden and prognosis. There are many accurate artificial intelligence tools to detect acute pulmonary embolism. Detection of chronic pulmonary embolism proves more challenging with further research required.Summary: There are numerous artificial intelligence tools being developed to identify and quantify many clinically relevant parameters in both pulmonary hypertension and related disease cohorts. These potentially provide accurate and efficient clinical information, impacting clinical decision-making.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"464-472"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309337/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141579183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic background of pulmonary (vascular) diseases - how much is written in the codes? 肺（血管）疾病的遗传背景--代码中写了多少？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-06-24 DOI: 10.1097/MCP.0000000000001090

Christina A Eichstaedt, Simon O Haas, Memoona Shaukat, Ekkehard Grünig

{"title":"Genetic background of pulmonary (vascular) diseases - how much is written in the codes?","authors":"Christina A Eichstaedt, Simon O Haas, Memoona Shaukat, Ekkehard Grünig","doi":"10.1097/MCP.0000000000001090","DOIUrl":"10.1097/MCP.0000000000001090","url":null,"abstract":"Purpose of review: To provide a comprehensive overview of the underlying genetic defects of pulmonary (vascular) diseases and novel treatment avenues.Recent findings: Pulmonary arterial hypertension (PAH) is the prime example of a pulmonary vascular disease, which can be caused by genetic mutations in some patients. Germline mutations in the BMPR2 gene and further genes lead to vessel remodelling, increase of pulmonary vascular resistance and onset of heritable PAH. The PAH genes with the highest evidence and strategies for genetic testing and counselling have been assessed and evaluated in 2023 by international expert consortia. Moreover, first treatment options have just arisen targeting the molecular basis of PAH.Summary: Apart from PAH, this review touches on the underlying genetic causes of further lung diseases including alpha 1 antitrypsin deficiency, cystic fibrosis, familial pulmonary fibrosis and lymphangioleiomyomatosis. We point out the main disease genes, the underlying pathomechanisms and novel therapies trying not only to relieve symptoms but to treat the molecular causes of the diseases.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"429-436"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141442285","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating the assessment of quality of life in care and research in pulmonary fibrosis. 将生活质量评估纳入肺纤维化护理和研究。

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-01 DOI: 10.1097/MCP.0000000000001095

Kerri I Aronson, Jeffrey J Swigris, Marlies Wijsenbeek

{"title":"Integrating the assessment of quality of life in care and research in pulmonary fibrosis.","authors":"Kerri I Aronson, Jeffrey J Swigris, Marlies Wijsenbeek","doi":"10.1097/MCP.0000000000001095","DOIUrl":"10.1097/MCP.0000000000001095","url":null,"abstract":"Purpose of review: Pulmonary fibrosis (PF) negatively influences health-related quality of life (HRQOL). Patients living with PF have voiced the desire for a focus on symptoms and HRQOL in both disease monitoring and treatment decisions.Recent findings: Currently available disease modifying treatments do little to impact HRQOL. Newer studies evaluating pharmacologic and nonpharmacologic therapies targeting symptoms and HRQOL in PF have been conducted with some promising results. There is increasing recognition of the importance of incorporating HRQOL as a higher tier endpoint in clinical trials. Disease-specific measure of HRQOL have been developed for those living with PF, and there is ongoing work to better understand the validity and reliability characteristics of these tools. In addition to research, there is recognition of the potential benefits of measuring HRQOL and symptoms in clinical practice in facilitate integrating patient perspective into care and allow for more personalized treatment approaches.Summary: There is increased momentum to discover treatments that impact HRQOL in PF. More work is desperately needed to identify better treatment targets, and to incorporate HRQOL and symptoms as higher tier endpoints in clinical trials. Further work is also needed to address the practicalities of integrating HRQOL measurement into clinical care.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"508-515"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141466835","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pulmonary vascular disease in chronic lung diseases: cause or comorbidity? 慢性肺病中的肺血管疾病：病因还是并发症？

IF 2.8 3区医学

Current Opinion in Pulmonary Medicine Pub Date : 2024-09-01 Epub Date: 2024-07-03 DOI: 10.1097/MCP.0000000000001091

Isabel Blanco, Rodrigo Torres-Castro, Joan Albert Barberà

{"title":"Pulmonary vascular disease in chronic lung diseases: cause or comorbidity?","authors":"Isabel Blanco, Rodrigo Torres-Castro, Joan Albert Barberà","doi":"10.1097/MCP.0000000000001091","DOIUrl":"10.1097/MCP.0000000000001091","url":null,"abstract":"Purpose of review: To provide timely and relevant insights into the complex relationship between pulmonary vascular disease (PVD) and chronic lung disease (CLD), focusing on the causative and consequential dynamics between these conditions.Recent findings: There are shared pathogenic mechanisms between pulmonary arterial hypertension (PAH) and group 3 pulmonary hypertension, including altered expression of mediators and growth factors implicated in both conditions. Factors such as hypoxia, hypoxemia, and hypercapnia also contribute to pulmonary vascular remodelling and endothelial dysfunction. However, the role of hypoxia as the sole driver of pulmonary hypertension in CLD is being reconsidered, particularly in chronic obstructive pulmonary disease (COPD), with evidence suggesting a potential role for cigarette smoke products in initiating pulmonary vascular impairment. On the other hand, interstitial lung disease (ILD) encompasses a group of heterogeneous lung disorders characterized by inflammation and fibrosis of the interstitium, leading to impaired gas exchange and progressive respiratory decline, which could also play a role as a cause of pulmonary hypertension.Summary: Understanding the intricate interplay between the pulmonary vascular compartment and the parenchymal and airway compartments in respiratory disease is crucial for developing effective diagnostic and therapeutic strategies for patients with PVD and CLD, with implications for both clinical practice and research.","PeriodicalId":11090,"journal":{"name":"Current Opinion in Pulmonary Medicine","volume":" ","pages":"437-443"},"PeriodicalIF":2.8,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141491245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0